Name | Number of supported studies | Average coverage | |
---|---|---|---|
peripheral blood | 19 studies | 38% ± 11% | |
lung | 18 studies | 32% ± 14% | |
intestine | 9 studies | 24% ± 8% | |
brain | 8 studies | 23% ± 10% | |
kidney | 7 studies | 23% ± 5% | |
liver | 6 studies | 29% ± 8% | |
lymph node | 5 studies | 33% ± 9% | |
bone marrow | 4 studies | 33% ± 11% | |
uterus | 4 studies | 35% ± 16% | |
breast | 4 studies | 25% ± 3% | |
prostate | 4 studies | 29% ± 10% | |
pancreas | 3 studies | 35% ± 17% | |
thymus | 3 studies | 45% ± 18% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
esophagus | 100% | 6618.41 | 1445 / 1445 | 100% | 249.15 | 183 / 183 |
ovary | 100% | 7424.91 | 180 / 180 | 100% | 180.70 | 429 / 430 |
lung | 100% | 9789.51 | 577 / 578 | 100% | 282.63 | 1154 / 1155 |
prostate | 100% | 7696.89 | 245 / 245 | 99% | 259.49 | 499 / 502 |
intestine | 100% | 10415.14 | 966 / 966 | 99% | 259.44 | 523 / 527 |
thymus | 100% | 14129.85 | 653 / 653 | 99% | 255.72 | 599 / 605 |
breast | 100% | 7729.64 | 459 / 459 | 99% | 253.03 | 1106 / 1118 |
uterus | 100% | 17633.52 | 170 / 170 | 99% | 293.28 | 454 / 459 |
bladder | 100% | 8528.29 | 21 / 21 | 99% | 246.23 | 498 / 504 |
stomach | 100% | 6614.31 | 359 / 359 | 99% | 247.10 | 282 / 286 |
liver | 100% | 14669.96 | 226 / 226 | 98% | 209.22 | 398 / 406 |
pancreas | 98% | 4562.06 | 323 / 328 | 98% | 194.60 | 174 / 178 |
kidney | 100% | 5821.00 | 89 / 89 | 95% | 203.65 | 859 / 901 |
brain | 85% | 3561.50 | 2233 / 2642 | 99% | 123.23 | 698 / 705 |
skin | 100% | 11624.33 | 1808 / 1809 | 81% | 104.72 | 384 / 472 |
adrenal gland | 100% | 6728.69 | 258 / 258 | 59% | 49.09 | 136 / 230 |
adipose | 100% | 7203.40 | 1204 / 1204 | 0% | 0 | 0 / 0 |
lymph node | 0% | 0 | 0 / 0 | 100% | 167.80 | 29 / 29 |
spleen | 100% | 6210.44 | 241 / 241 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 100% | 198.82 | 45 / 45 |
ureter | 0% | 0 | 0 / 0 | 100% | 60.13 | 1 / 1 |
blood vessel | 100% | 6108.32 | 1330 / 1335 | 0% | 0 | 0 / 0 |
heart | 94% | 3781.20 | 812 / 861 | 0% | 0 | 0 / 0 |
peripheral blood | 88% | 6324.40 | 818 / 929 | 0% | 0 | 0 / 0 |
muscle | 49% | 1036.53 | 392 / 803 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 49% | 35.65 | 39 / 80 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
GO_0009897 | Cellular component | external side of plasma membrane |
GO_0031410 | Cellular component | cytoplasmic vesicle |
GO_0016020 | Cellular component | membrane |
GO_0038023 | Molecular function | signaling receptor activity |
GO_0005515 | Molecular function | protein binding |
Gene name | TMEM123 |
Protein name | Alternative protein TMEM123 Transmembrane protein 123 Porimin (Keratinocytes-associated transmembrane protein 3) (KCT-3) (Pro-oncosis receptor inducing membrane injury) (Transmembrane protein 123) |
Synonyms | KCT3 UNQ641/PRO1271 PSEC0111 |
Description | FUNCTION: Implicated in oncotic cell death, characterized by cell swelling, organelle swelling, vacuolization and increased membrane permeability. . |
Accessions | E9PJW0 ENST00000398136.7 [Q8N131-1] ENST00000531103.5 ENST00000532161.5 E9PSB1 L8EBC6 E9PKT4 Q8N131 ENST00000528969.5 ENST00000526676.1 ENST00000361236.7 [Q8N131-2] |